vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and indie Semiconductor, Inc. (INDI). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $58.0M, roughly 1.4× indie Semiconductor, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -53.8%, a 60.7% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -0.0%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-16.1M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
indie Semiconductor is a fabless semiconductor manufacturer focused on designing high-performance mixed-signal and embedded system-on-chip solutions for the automotive industry. Its products support advanced driver assistance systems, in-vehicle infotainment, connected car, and electric vehicle applications, serving global auto OEMs and tier 1 suppliers across major global markets.
BLLN vs INDI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $58.0M |
| Net Profit | $5.7M | $-31.2M |
| Gross Margin | 69.9% | 37.3% |
| Operating Margin | 11.5% | -58.5% |
| Net Margin | 6.8% | -53.8% |
| Revenue YoY | 117.4% | -0.0% |
| Net Profit YoY | 138.3% | 9.1% |
| EPS (diluted) | $0.10 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $58.0M | ||
| Q3 25 | $83.5M | $53.7M | ||
| Q2 25 | — | $51.6M | ||
| Q1 25 | — | $54.1M | ||
| Q4 24 | — | $58.0M | ||
| Q3 24 | $38.4M | $54.0M | ||
| Q2 24 | — | $52.4M | ||
| Q1 24 | — | $52.4M |
| Q4 25 | — | $-31.2M | ||
| Q3 25 | $5.7M | $-38.3M | ||
| Q2 25 | — | $-39.0M | ||
| Q1 25 | — | $-34.5M | ||
| Q4 24 | — | $-34.4M | ||
| Q3 24 | $-14.9M | $-49.7M | ||
| Q2 24 | — | $-19.2M | ||
| Q1 24 | — | $-31.2M |
| Q4 25 | — | 37.3% | ||
| Q3 25 | 69.9% | 40.1% | ||
| Q2 25 | — | 40.6% | ||
| Q1 25 | — | 41.7% | ||
| Q4 24 | — | 42.6% | ||
| Q3 24 | 52.6% | 39.3% | ||
| Q2 24 | — | 42.2% | ||
| Q1 24 | — | 42.5% |
| Q4 25 | — | -58.5% | ||
| Q3 25 | 11.5% | -71.4% | ||
| Q2 25 | — | -83.3% | ||
| Q1 25 | — | -72.0% | ||
| Q4 24 | — | -58.4% | ||
| Q3 24 | -32.9% | -92.5% | ||
| Q2 24 | — | -70.0% | ||
| Q1 24 | — | -94.8% |
| Q4 25 | — | -53.8% | ||
| Q3 25 | 6.8% | -71.3% | ||
| Q2 25 | — | -75.6% | ||
| Q1 25 | — | -63.9% | ||
| Q4 24 | — | -59.2% | ||
| Q3 24 | -38.8% | -92.1% | ||
| Q2 24 | — | -36.6% | ||
| Q1 24 | — | -59.6% |
| Q4 25 | — | $-0.16 | ||
| Q3 25 | $0.10 | $-0.19 | ||
| Q2 25 | — | $-0.20 | ||
| Q1 25 | — | $-0.18 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | $-1.47 | $-0.28 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $145.5M |
| Total DebtLower is stronger | $55.0M | $353.4M |
| Stockholders' EquityBook value | $-239.5M | $358.0M |
| Total Assets | $327.5M | $840.8M |
| Debt / EquityLower = less leverage | — | 0.99× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $145.5M | ||
| Q3 25 | $195.2M | $160.9M | ||
| Q2 25 | — | $192.6M | ||
| Q1 25 | — | $236.6M | ||
| Q4 24 | — | $274.2M | ||
| Q3 24 | — | $96.9M | ||
| Q2 24 | — | $112.3M | ||
| Q1 24 | — | $138.2M |
| Q4 25 | — | $353.4M | ||
| Q3 25 | $55.0M | $353.5M | ||
| Q2 25 | — | $352.5M | ||
| Q1 25 | — | $379.0M | ||
| Q4 24 | — | $381.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $358.0M | ||
| Q3 25 | $-239.5M | $369.2M | ||
| Q2 25 | — | $390.4M | ||
| Q1 25 | — | $405.6M | ||
| Q4 24 | — | $417.9M | ||
| Q3 24 | $-242.9M | $458.6M | ||
| Q2 24 | — | $470.7M | ||
| Q1 24 | — | $432.9M |
| Q4 25 | — | $840.8M | ||
| Q3 25 | $327.5M | $855.1M | ||
| Q2 25 | — | $867.6M | ||
| Q1 25 | — | $909.0M | ||
| Q4 24 | — | $941.4M | ||
| Q3 24 | — | $797.5M | ||
| Q2 24 | — | $797.3M | ||
| Q1 24 | — | $803.6M |
| Q4 25 | — | 0.99× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 0.91× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-14.4M |
| Free Cash FlowOCF − Capex | $6.5M | $-16.1M |
| FCF MarginFCF / Revenue | 7.7% | -27.8% |
| Capex IntensityCapex / Revenue | 8.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-71.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-14.4M | ||
| Q3 25 | $13.8M | $-6.2M | ||
| Q2 25 | — | $-7.6M | ||
| Q1 25 | — | $-29.0M | ||
| Q4 24 | — | $-6.7M | ||
| Q3 24 | — | $-22.8M | ||
| Q2 24 | — | $-19.7M | ||
| Q1 24 | — | $-9.3M |
| Q4 25 | — | $-16.1M | ||
| Q3 25 | $6.5M | $-10.3M | ||
| Q2 25 | — | $-13.6M | ||
| Q1 25 | — | $-31.4M | ||
| Q4 24 | — | $-8.6M | ||
| Q3 24 | — | $-29.3M | ||
| Q2 24 | — | $-23.4M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | — | -27.8% | ||
| Q3 25 | 7.7% | -19.2% | ||
| Q2 25 | — | -26.4% | ||
| Q1 25 | — | -58.0% | ||
| Q4 24 | — | -14.8% | ||
| Q3 24 | — | -54.3% | ||
| Q2 24 | — | -44.7% | ||
| Q1 24 | — | -22.3% |
| Q4 25 | — | 3.0% | ||
| Q3 25 | 8.8% | 7.8% | ||
| Q2 25 | — | 11.6% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | — | 7.0% | ||
| Q1 24 | — | 4.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
INDI
| Products | $55.7M | 96% |
| Services | $2.3M | 4% |
